A Phase 1 interventional study of sitagliptin phosphate and metformin hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 171st largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 23 in phase 1, and was the 60th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 150th largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 55 in phase 1, and was the 69th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: sitagliptin phosphate · Drug: Comparator: placebo metformin
Drug: metformin hydrochloride · Drug: Comparator: placebo sitagliptin
Co-administration of sitagliptin and metformin
Drug: sitagliptin phosphate · Drug: metformin hydrochloride
Co-administration of placebo to sitagliptin and placebo to metformin
Drug: Comparator: placebo sitagliptin · Drug: Comparator: placebo metformin
Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
Also known as: Januvia
Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
Also known as: Glucophage
Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations
Meal was given 2 hours postdose. Blood samples for determination of active GLP-1 concentration were collected (4 hours postmeal) on Day 2 in each treatment period.
Time frame: 6 hours postdose (4 hours postmeal) on Day 2
β-cell Sensitivity
β-cell sensitivity was defined as the incremental post-prandial 4-hour area under the curve (AUC) for insulin secretion rate (ISR) normalized by the incremental post-prandial 4-hour plasma glucose AUC.
Time frame: 6 hour post-dose (4 hour postmeal) on Day 2
Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations
Meal was given 2 hours postdose. Blood samples for determination of glucose concentration were collected (4 hours postmeal) on Day 2 in each treatment period.
Time frame: 6 hours postdose (4 hours postmeal) on Day 2
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | All Participants |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
Meal was given 2 hours postdose. Blood samples for determination of active GLP-1 concentration were collected (4 hours postmeal) on Day 2 in each treatment period.
| picomolar | All Participants |
|---|---|
| Sitagliptin + placebo metformin | 6.00 (4.53 to 7.94) |
| Metformin + placebo sitagliptin | 4.09 (3.09 to 5.42) |
| Sitagliptin + metformin | 7.22 (5.45 to 9.55) |
| Placebo sitagliptin + placebo metformin | 1.55 (1.17 to 2.05) |
β-cell sensitivity was defined as the incremental post-prandial 4-hour area under the curve (AUC) for insulin secretion rate (ISR) normalized by the incremental post-prandial 4-hour plasma glucose AUC.
| (ng/min)/(mg/dL)*10^ -3 | All Participants |
|---|---|
| Sitagliptin + placebo metformin, n=17 | 19.50 (11.89 to 32.00) |
| Metformin + placebo sitagliptin, n=17 | 25.71 (15.67 to 42.18) |
| Sitagliptin + metformin, n=18 | 26.39 (16.18 to 43.05) |
| Placebo sitagliptin + placebo metformin, n=18 | 15.44 (9.46 to 25.19) |
Meal was given 2 hours postdose. Blood samples for determination of glucose concentration were collected (4 hours postmeal) on Day 2 in each treatment period.
| mg/dL | All Participants |
|---|---|
| Sitagliptin + placebo metformin | 42.30 (30.51 to 54.08) |
| Metformin + placebo sitagliptin | 29.33 (17.55 to 41.12) |
| Sitagliptin + metformin | 20.02 (8.24 to 31.81) |
| Placebo sitagliptin + placebo metformin | 51.02 (39.24 to 62.81) |
Collected over 43 days (four 2-day treatment periods, a 7-day washout interval between each treatment period, and approximately 14 days following the last dose of study treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin + Placebo Metformin | — | 0/18 (0%) | 4/18 (22.2%) |
| Metformin + Placebo Sitagliptin | — | 0/18 (0%) | 3/18 (16.7%) |
| Sitagliptin + Metformin | — | 0/18 (0%) | 3/18 (16.7%) |
| Placebo Sitagliptin + Placebo Metformin | — | 0/18 (0%) | 4/18 (22.2%) |
| Event | Sitagliptin + Placebo Metformin | Metformin + Placebo Sitagliptin | Sitagliptin + Metformin | Placebo Sitagliptin + Placebo Metformin |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/18 | 1/18 | 1/18 | 2/18 |
| Iron Deficiency anaemiaBlood and lymphatic system disorders | 1/18 | 0/18 | 0/18 | 0/18 |
| Conjunctival haemorrhageEye disorders | 1/18 | 0/18 | 0/18 | 0/18 |
| Vision blurredEye disorders | 0/18 | 0/18 | 0/18 | 1/18 |
| DiarrhoeaGastrointestinal disorders | 0/18 | 0/18 | 1/18 | 0/18 |
| DyspepsiaGastrointestinal disorders | 1/18 | 1/18 | 0/18 | 1/18 |
| NauseaGastrointestinal disorders | 0/18 | 0/18 | 1/18 | 0/18 |
| VomitingGastrointestinal disorders | 0/18 | 0/18 | 0/18 | 1/18 |
| FatigueGeneral disorders | 0/18 | 0/18 | 0/18 | 1/18 |
| Vessel puncture site painGeneral disorders | 0/18 | 0/18 | 0/18 | 1/18 |
| Age, Categorical(Participants) | All Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 17 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 5 |
| Male | 13 |
| Region of Enrollment(participants) | All Participants |
|---|---|
| United States | 18 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Dec 2008 to primary completion in Apr 2009, 4 months.
Results were first posted in Nov 2011, 2 years 6 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin